The results of a new study released by the National Association of Chain Drug Stores (NACDS) predict problems ahead for Medicare beneficiaries with diabetes if blood glucose monitors and related testing supplies are included in the new Medicare competitive acquisition program scheduled to start in 2007.
The study, conducted for the chain drug industry group by Health Policy R&D, raises particular concerns about the ability of pharmacies to continue to supply blood glucose monitors under the new program. These monitors, which NACDS called "an integral part of disease management for patients with diabetes," are currently covered under the durable medical equipment benefit in Medicare Part B.
Shifting glucose monitors and supplies to the competitive bidding system "could create a situation where Medicare beneficiaries with diabetes might be unable to access all aspects of their glucose management regimenincluding their medications, monitors, supplies, and related professional servicesfrom their community pharmacy of choice," NACDS said.
"CMS [Centers for Medicare & Medicaid Services] needs to be aware that competitive bidding for blood glucose meters and related supplies under Medicare Part B could potentially do more harm than good for beneficiaries," NACDS Senior Vice President Mary Ann Wagner said.
The Oncology Care Pharmacist in Health-System Pharmacy
According to the National Cancer Institute, almost 40% of men and women will be given a diagnosis of some form of cancer in their lifetime.
News from the year's biggest meetings
Clinical features with downloadable PDFs